SGO1: Potential Drug Target Or Biomarker (G151648)

Target Name: SGO1

NCBI ID: G151648

SGO1

SGO1: Potential Drug Target Or Biomarker

SGO1 (Shugoshin 1EF protein) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the evolutionarily conserved superfamily of transmembrane proteins, which includes proteins involved in various cellular processes, including signaling, intracellular transport, and tissue structure. SGO1 has been shown to play a role in several physiological processes, including cell signaling, inflammation, and regeneration. As a result, SGO1 has potential as a drug target or biomarker.

SGO1 is a 21-kDa protein that is expressed in the brain, heart, and kidneys. It is characterized by a long N-terminus that contains a unique domain that is involved in protein-protein interactions and a short C-terminus that contains a cytoplasmic tail. SGO1 is a member of the evolutionarily conserved superfamily of transmembrane proteins, which includes proteins involved in various cellular processes, including signaling, intracellular transport, and tissue structure.

SGO1 has been shown to play a role in several physiological processes. For example, SGO1 has been shown to be involved in cell signaling, specifically in the regulation of cell adhesion and migration. SGO1 has been shown to interact with several other proteins, including the transcription factor NF-kappa-B and the protein kinase PDGFR-尾. These interactions may be involved in the regulation of cellular processes such as cell adhesion, migration, and survival.

In addition to its role in cell signaling, SGO1 has also been shown to be involved in inflammation. SGO1 has been shown to interact with several proteins involved in inflammation, including the transcription factor NF-kappa-B and the protein kinase IRAK4. These interactions may be involved in the regulation of inflammatory responses and the regulation of pain.

SGO1 has also been shown to be involved in tissue regeneration. SGO1 has been shown to play a role in the regulation of cell proliferation and differentiation, which may be involved in tissue regeneration. of the proliferation of neural stem cells, which are important for the development and maintenance of neural tissue.

SGO1 has also been shown to be involved in several other physiological processes, including cell signaling, inflammation, and tissue regeneration. As a result, SGO1 has potential as a drug target or biomarker.

In conclusion, SGO1 is a protein that is expressed in various tissues of the body and is involved in several physiological processes. Its unique domain and interactions with other proteins make it a potential drug target or biomarker. Further research is needed to fully understand the role of SGO1 in cellular processes and its potential as a drug target or biomarker.

Protein Name: Shugoshin 1

Functions: Plays a central role in chromosome cohesion during mitosis by preventing premature dissociation of cohesin complex from centromeres after prophase, when most of cohesin complex dissociates from chromosomes arms. May act by preventing phosphorylation of the STAG2 subunit of cohesin complex at the centromere, ensuring cohesin persistence at centromere until cohesin cleavage by ESPL1/separase at anaphase. Essential for proper chromosome segregation during mitosis and this function requires interaction with PPP2R1A. Its phosphorylated form is necessary for chromosome congression and for the proper attachment of spindle microtubule to the kinetochore. Necessary for kinetochore localization of PLK1 and CENPF. May play a role in the tension sensing mechanism of the spindle-assembly checkpoint by regulating PLK1 kinetochore affinity. Isoform 3 plays a role in maintaining centriole cohesion involved in controlling spindle pole integrity. Involved in centromeric enrichment of AUKRB in prometaphase

The "SGO1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SGO1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets